United Therapeutics (UTHR) Receives a Buy from Oppenheimer

By Carrie Williams

In a report released yesterday, Hartaj Singh from Oppenheimer maintained a Buy rating on United Therapeutics (UTHRResearch Report), with a price target of $155. The company’s shares closed yesterday at $99.30, close to its 52-week low of $98.18.

Singh commented:

“United Therapeutics (UTHR) reported 1Q19 sales/earnings and provided a business update to investors on 05/01. We had been cautious heading into a seasonally weak 1Q reporting season; however, the company comfortably beat OPCO (see exhibits inside) and consensus expectations (7% sales and 2% non- GAAP beat). Also, management commentary indicated that the treprostinil franchise all grew due to patient additions and price increases (low-single digits historically). If this trend sustains for the rest of the year—and management does not understand why it should not—OPCO and consensus sales/earnings numbers for 2019 could be 10% to 20% too low. With an expected RemUnity (Deka) pump approval in 2Q19 and Unituxin’s DISTINCT SCLC readout by ~YE19/1Q20, we stay bullish.”

According to TipRanks.com, Singh is a 3-star analyst with an average return of 1.9% and a 42.5% success rate. Singh covers the Healthcare sector, focusing on stocks such as SELLAS Life Sciences Group Inc, Strongbridge Biopharma Plc, and Catabasis Pharmaceuticals.

The word on The Street in general, suggests a Hold analyst consensus rating for United Therapeutics with a $134.14 average price target.

See today’s analyst top recommended stocks >>

United Therapeutics’ market cap is currently $4.33B and has a P/E ratio of 7.38. The company has a Price to Book ratio of 1.55.

Based on the recent corporate insider activity of 73 insiders, corporate insider sentiment is neutral on the stock. Most recently, in March 2019, Tommy Thompson, a Director at UTHR bought 17,100 shares for a total of $900,315.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

United Therapeutics Corp. operates as a biotechnology company, which engages in the development and commercialization of products for patients with chronic and life-threatening diseases. It markets and sells commercial therapies to treat pulmonary arterial hypertension and high-risk neuroblastoma.